We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aventis-Pasteur has said it will make 2.6 million extra doses of the flu vaccine this year, the latest among several ongoing public and private efforts to offset a massive U.S. flu vaccine shortage.
Republicans and Democrats have pointed the finger of blame at one another as federal authorities scramble to fulfill a massive shortfall in the nation’s flu vaccine supply.
Evaluating how drug firms compute the average sales price (ASP) for drugs reimbursed under Medicare and determining the extent to which the FDA monitors drugmakers' postmarketing study commitments are among the investigations HHS' Office of Inspector General (OIG) plans to undertake in fiscal 2005.
With the U.S. flu-vaccine supply cut in half, HHS plans to invest heavily to stockpile antiviral drugs as the next line of defense for fighting influenza. Antiviral drugs have the potential to prevent, as well as treat, influenza by stopping the spread of the flu virus.
HHS will hold a public meeting Nov. 8 to weigh new ideas and promote new solutions to speed the development of effective new drugs and biological products.
The widely watched U.S. Pharmacopeia (USP) model guidelines for Medicare drug plans will allow any eligible Medicare drug to appear on a plan sponsor’s formulary, according to the head of USP who countered criticism that the guidelines fail to provide patients with access to needed medicines.
HHS’s special task force on medical technology innovation will convene in Washington, D.C., next month to obtain public input on the steps the agency should take to stimulate technology development in the medical industry.
Determining the extent to which the FDA monitors drugmakers' postmarketing study commitments and evaluating how drug firms compute the average sales price (ASP) for drugs reimbursed under Medicare are among the investigations HHS' Office of Inspector General (OIG) plans to undertake in fiscal 2005.
Health regulators in the UK last week suspended influenza vaccine maker Chiron’s license to manufacture Fluvirin, leaving the U.S. with a severe shortage of flu shots.
Sponsors of Medicare drug plans may not be required to cover biologics that treat rare diseases and disorders, according to the Biotechnology Industry Organization (BIO), which urged federal regulators to ensure drug plans include the therapies.